SUBSCRIBE
SUBSCRIBE
News   Policy

US FDA Objects to Dendreon Corporation Promotions for Provenge

August 9, 2010 | 
1 min read
Reuters -- Dendreon Corp exaggerated the benefits of its novel prostate cancer vaccine and downplayed risks in some sales materials for the product, U.S. regulators said in a letter released on Friday.
Legal Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Pictured: (From L) Joe Ross, Camille Bedrosian, Emil Kakkis and Heather McKenzie
Rare diseases
FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent
June 24, 2025
 · 
3 min read
 · 
Heather McKenzie
A group of people sitting before microphones at a table on a stage
Government
Acting CDER Head Becomes Latest in String of FDA Leaders to Leave Agency
June 23, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
A pill with the Amercan and Chinese flag wrapped around it
Government
FDA Freezes Trials Shipping Cells to China, ‘Other Hostile Countries’
June 20, 2025
 · 
2 min read
 · 
Tristan Manalac
Business
Navigating Funding Freezes and AI Frontiers
June 20, 2025
 · 
1 min read
 · 
Lori Ellis